Scinai Yahoo@4x300x400
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
September 13, 2023 16:13 ET | Scinai Immunotherapeutics Ltd.
Scinai’s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis Stratum corneum regained normal appearance in laboratory 3D skin model Results from ex-vivo study...
Scinai Logo.jpg
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
September 06, 2023 06:00 ET | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to...
BiondVax LOGO.png
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
June 05, 2023 07:00 ET | BiondVax Pharmaceuticals Ltd.
Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential...
BiondVax LOGO.png
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
January 06, 2023 07:15 ET | BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated...
BiondVax LOGO.png
BiondVax CEO Issues Letter to Shareholders
December 30, 2022 07:30 ET | BiondVax Pharmaceuticals Ltd.
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing...